A multicentre efficacy and safety study of the single contraceptive implant Implanon®

An open, multicentre study was performed to assess efficacy, safety and acceptability of the single-rod contraceptive implant Implanon((R)). The study involved 635 young healthy women, who were sexually active and of childbearing potential, The women were followed up every 3 months over the entire study period. Originally the study was designed for 2 years, but was extended to 3 years in a group of 147 women from two centres. Altogether, 21 centres in nine different countries participated, The average age of the women was 29 years (range 18-42 years), of whom 83.5% had been pregnant in the past. No pregnancy occurred during treatment with Implanon((R)), resulting in a Pearl Index of 0 (95% confidence interval: 0.0-0.2). In the first 2 years, 31% had discontinued the treatment. Of the 147 women in the study extension, nine discontinued (6%) treatment, Bleeding irregularities was the main reason for discontinuation during the first 2 years of use (17.2%) and adverse experiences in the third year (3.4%), Implant insertion and removal were fast and uncomplicated in the vast majority (97%) of cases. Return of fertility was prompt. In conclusion, Implanon((R)) has excellent contraceptive action during its lifetime of 3 years, The safety profile is acceptable and not essentially different from progestogens in general.